Careers Search for: Biology Chemistry Manufacturing About Us Contact Us Antibody Discovery at Abzena Identify and develop lead candidates against a vast range of targets Discovery Phage display, sequencing and developability assessment The biopharmaceutical development process starts with target identiﬁcation and antibody discovery. Abzena oﬀers multiple approaches to antibody discovery and the isolation, development and selection of lead antibodies. Antibody Discovery Abzena’s antibody discovery capability is based on the latest and most efficient hybridoma generation technologies coupled with high throughput robotic colony picking and liquid handling for highly efficient hybridoma screening. Read more >>> Hybridoma Sequencing Abzena’s platform for mRNA sequencing can determine the DNA and amino acid sequence of your antibody. Sequencing can be performed for IgG and IgM monoclonal antibodies produced by human, mouse and rat hybridoma cell lines. Read more >>> Developability Assessment Many physicochemical modiﬁcations can adversely impact on the molecular integrity of biologic molecules. Abzena can perform an in silico assessment to identify a number of potential sequence liabilities which, if not addressed, could lead to manufacturing challenges at a later stage. Read more >>> Interested in our services? Get In Touch Quick Links Home Careers Media Contact Us Contact Details Enquiries Cambridge, UK Babraham Research Campus Cambridge CB22 3AT United Kingdom +44 1223 903498 San Diego, CA, USA 8810 Rehco Rd San Diego CA 92121 United States +1 858-550-4094 Bristol, PA, USA 360 George Patterson Blvd. Bristol PA 19007 United States +1 215-788-3603 © Abzena Ltd | Registered Number: 08957107 | VAT Number: 125470235 Terms & Conditions | Complaints Policy | Cookie Policy | Privacy Policy